Stocktoria
Scinai Immunotherapeutics Ltd. SCNI
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2007-06-07
Scinai Immunotherapeutics Ltd. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $658,000 | — | — | — |
| Gross profit | -$2.7M | -$580,000 | — | — | — |
| R&D expense | $2.4M | $5.5M | $5.2M | $5.8M | $3.2M |
| SG&A expense | $2.5M | $2.5M | $4.5M | $5.3M | $7.6M |
| Operating income | -$7.5M | -$8.6M | -$9.7M | -$11.1M | -$10.9M |
| Interest expense | — | — | $343,000 | $351,000 | $336,000 |
| Net income | -$8.3M | $4.8M | -$6.5M | -$5.8M | -$8.2M |
| EPS (diluted) | — | — | $0.00 | $0.01 | $-0.02 |
| Operating cash flow | -$6.0M | -$6.3M | -$9.4M | $7.3B | -$7.4M |
| Free cash flow | -$6.1M | -$6.3M | -$10.0M | $7.3B | -$7.6M |
| Cash & equivalents | $1.7M | $2.0M | $4.9M | $14.1M | $17.4M |
| Total assets | $11.6M | $13.4M | $17.5M | $27.1M | $32.0M |
| Shareholders' equity | $8.1M | $10.0M | -$4.6M | -$1.8M | $982,000 |
Growth · year-over-year · Revenue CAGR 99.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | +99.2% | — | — | — | — |
| Net income growth | -273.2% | — | — | — | — |
| EPS growth | — | — | -60.0% | — | — |
| Free cash flow growth | — | — | -100.1% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.